A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

Name: A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
Published: 2022
License: Public Domain

Agios Pharmaceuticals, Inc. · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

anemia metabolic-diseases

pediatric pyruvate kinase deficiency, pediatric hemolytic anemia, anemia, hematologic diseases, metabolic diseases, mitapivat, ag-348, activate-kidst, pk deficiency, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

Related documents